10207 Results

People

  1. Gonen
    Gonen
  2. Vickers
    Vickers
  3. Panageas
    Panageas
  4. Patil
    Patil
  5. Schultz
    Schultz
  6. Giralt
    Giralt
  7. Zhang
    Zhang
  8. Jarnagin
    Jarnagin
  9. Heller
    Heller
  10. D'Angelica
    D'Angelica

Groups

  1. Epidemiology and Biostatistics (10207)
  2. Biostatistics Service (6564)
  3. Department of Medicine (4907)
  4. Population Sciences Research Program (4867)
  5. Surgery (3680)
  6. Survivorship Research (3597)
  7. Solid Tumor Oncology Division (3294)
  8. GSK Faculty (2807)
  9. Center for Pancreatic Cancer Research (2495)
  10. Health Outcomes Research Group (2069)
  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (6429)
  2. Meeting Abstract (3245)
  3. Editorial (116)
  4. Review (93)
  5. Research Letter (80)
  6. Correspondence (77)
  7. Conference Paper (54)
  8. Miscellaneous (52)
  9. Book Section (43)
  10. Guidelines (13)
  11. Book Whole (5)
Groups
  1. Epidemiology and Biostatistics (10207)
  2. Biostatistics Service (6564)
  3. Department of Medicine (4907)
  4. Population Sciences Research Program (4867)
  5. Surgery (3680)
  6. Survivorship Research (3597)

More Groups

People
  1. Mithat Gonen (1028)
  2. Andrew Vickers (880)
  3. Sean Devlin (601)
  4. Katherine Panageas (512)
  5. Sujata Patil (511)
  6. Nikolaus Schultz (486)

More People

Years
  1. 2025 (209)
  2. 2024 (622)
  3. 2023 (692)
  4. 2022 (732)
  5. 2021 (610)
  6. 2020 (625)

More Years

Publications
  1. Journal of Clinical Oncology (1374)
  2. Blood (534)
  3. Annals of Surgical Oncology (462)
  4. Cancer Research (274)
  5. International Journal of Radiation Oncology, Biology, Physics (258)
  6. Clinical Cancer Research (250)

More Publications

Publishers
  1. American Society of Clinical Oncology (1487)
  2. Elsevier Inc. (1206)
  3. Springer (925)
  4. American Association for Cancer Research (761)
  5. Elsevier Science, Inc. (685)
  6. American Society of Hematology (601)

More Publishers

Results (10207)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Single cell whole genome measurement of genomic heterogeneity and clonal evolution in multiple myeloma
    Meeting Abstract

    McPherson, A.; Maclachlan, K.; Myers, M.; Satas, G.; Garcés, J. J.; Lee, H.; Bahlis, N. J.; Usmani, S.; Shah, S.; Maura, F.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Associations between sociodemographic characteristics and colorectal cancer screening in a large VA cohort, 2002-2018
    Meeting Abstract

    Kirschenbaum, J. D.; Qian, Y. Z.; Nandi, S.; Kwon, S.; Zauber, A. G.; Dominitz, J. A.; Sherman, S.; Liang, P. S.
    American Journal of Gastroenterology (2024)

    Fulltext@MSK | Save
  • New clinical trial design borrowing information across patient subgroups based on fusion-penalized regression models
    Journal Article

    Kerioui, M.; Iasonos, A.; Gönen, M.; Arfé, A.
    Statistical Methods in Medical Research (2024)

    Fulltext@MSK | Save
  • Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax
    Journal Article

    Valtis, Y. K.; Nemirovsky, D.; Derkach, A.; Sharan, S.; Kabel, C.; Ortiz, R.; Thompson, M. C.; Roeker, L. E.; Geyer, M. B.
    Blood Advances (2024)

    Fulltext@MSK | Save